Skinbiotherap. Regulatory News (SBTX)

22 March 2022

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Investor Presentation - Interim Financial Results

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that Stuart Ashman, CEO, & Doug Quinn, CFO, will provide an update to investors on the Company's interim financial results via the Investor Meet Company platform on 29th March 2022 at 09:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics plc via:

https://www.investormeetcompany.com/skinbiotherapeutics-plc/register-investor

Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

For more information please contact:

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.